ClinicalTrials.gg
RecruitingNCT07601711SD-CRABUpdated May 22, 2026

Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study

An observational study in Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection and Pneumonia, sponsored by Sichuan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Sichuan Provincial People's Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
73rd of 164
200 · median 180
Started
2025
with 19 others
Observational
165 of 286
51 open now
Primary completion
2027-11
later than 74 of 105 live
Registered
256th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 73rd largest by planned enrollment of the 164 observational ones that give a count, is one of 20 that started in 2025, is one of 165 observational ones, reaches primary completion later than 74 of the 105 other live ones, and was the 256th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

93 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.

The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.

To reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.

Read the detailed description

This is a single-center real-world observational cohort study including hospitalized adult patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients will be classified into two groups based on treatment exposure: those receiving sulbactam-durlobactam and those receiving alternative anti-CRAB regimens during the same period.

The study aims to evaluate the effectiveness and safety of sulbactam-durlobactam in high-risk populations, including transplant recipients and critically ill patients. The primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, ICU length of stay, duration of mechanical ventilation, and treatment-related adverse events.

To minimize bias inherent in observational studies, propensity score matching, inverse probability of treatment weighting (IPTW), and multivariable regression models will be applied to adjust for baseline differences between groups. Landmark analysis will be conducted to address time-related biases.

A nested therapeutic drug monitoring (TDM) sub-cohort will be included. Plasma samples will be collected at predefined time points within a dosing interval, and drug concentrations will be measured using validated LC-MS/MS methods. Population pharmacokinetic modeling will be performed to estimate exposure parameters, including Cmin, Cmax, and AUC. The relationship between drug exposure and clinical outcomes, as well as PK/PD target attainment, will be further explored.

Subgroup analyses will be conducted according to infection status (confirmed infection vs. donor-derived colonization or infection).

03

Conditions studied

  • Carbapenem-Resistant Acinetobacter Baumannii Infection
  • Bloodstream Infection
  • Pneumonia
  • Sepsis

Keywords

  • CRAB Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospitalized adult patients receiving anti-CRAB antimicrobial therapy in real-world clinical practice, including:

  1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection; or
  2. transplant recipients with donor-derived CRAB colonization or infection receiving early targeted therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:

    1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or
    2. transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.
  • Treatment initiation time can be clearly determined.
  • Availability of clinical outcome data.

Exclusion criteria

Exclusion Criteria:

  • Colonization without evidence of active infection.
  • Missing key clinical data.
  • Inability to determine treatment initiation time.
  • Pregnancy or lactation.
  • Patients considered unsuitable by investigators.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Sulbactam-Durlobactam Group

    Patients receiving sulbactam-durlobactam within 48 hours after treatment initiation.

    Drug: Sulbactam-Durlobactam

  • Non-Sulbactam-Durlobactam Group

    Patients receiving alternative anti-CRAB regimens during the same period without sulbactam-durlobactam.

Interventions

  • DrugSulbactam-Durlobactam

    Sulbactam-durlobactam administered according to routine clinical practice for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infection.

06

What researchers measure

Primary outcomes

  1. 28-day All-Cause Mortality

    All-cause mortality occurring within 28 days after initiation of anti-CRAB therapy.

    Time frame: Up to 28 days after initiation of anti-CRAB therapy

Secondary outcomes

  1. Clinical Failure

    Clinical failure defined as lack of clinical improvement, need for escalation of antimicrobial therapy, or death.

    Time frame: Up to 28 days after initiation of anti-CRAB therapy

  2. Length of ICU stay

    Duration of ICU stay measured from ICU admission to ICU discharge.

    Time frame: Up to 90 days after ICU admission

  3. Time to clinical improvement

    Time from initiation of anti-CRAB therapy to predefined clinical improvement.

    Time frame: Up to 28 days after initiation of anti-CRAB therapy

  4. Microbiological eradication

    Microbiological eradication confirmed by follow-up culture negativity.

    Time frame: Up to 14 days after initiation of anti-CRAB therapy

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023 Sep;23(9):1072-1084. doi: 10.1016/S1473-3099(23)00184-6. Epub 2023 May 11. PubMed 37182534 ↗
  • Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21. PubMed 29276051 ↗
  • Covvey JR, Guarascio AJ. Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex. Expert Rev Anti Infect Ther. 2024 Nov;22(11):925-934. doi: 10.1080/14787210.2024.2400703. Epub 2024 Sep 8. PubMed 39234753 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to institutional policies and patient privacy protection.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2026
First posted
May 22, 2026
StartActual
Nov 11, 2025
Primary completionEst.
Nov 11, 2027
CompletionEst.
Nov 11, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07601711
Lead sponsor
Sichuan Provincial People's Hospital
Responsible party
Lingai Pan (Associate Chief Physician, Department of Critical Care Medicine, Sichuan Provincial People's Hospital) — Principal investigator
First posted
May 22, 2026
Start date
Nov 11, 2025
Primary completion
Nov 11, 2027 (estimated)
Completion
Nov 11, 2027 (estimated)
Last update
May 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion